PDF(Pubmed)
Abstract：
BACKGROUND: The association between Apolipoprotein A5 (APOA5) genetic polymorphisms and susceptibility to metabolic syndrome (MetS) has been established by many studies, but there have been conflicting results from the literature. We performed a meta-analysis of observational studies to evaluate the association between APOA5 gene polymorphisms and the prevalence of MetS.
METHODS: PubMed, Web of Science, Embase, and Scopus were searched up to April 2024. The random effects model was used to estimate the odds ratios (ORs) and 95% confidence intervals (CI) of the association between APOA5 gene polymorphisms and the prevalence of MetS development. The potential sources of heterogeneity were evaluated by subgroup analyses and sensitivity analyses.
RESULTS: A total of 30 studies with 54,986 subjects (25,341 MetS cases and 29,645 healthy controls) were included. The presence of rs662799 and rs651821 polymorphisms is associated with an approximately 1.5-fold higher likelihood of MetS prevalence (OR = 1.42, 95% CI: 1.32, 1.53, p < 0.001; I2 = 67.1%; P-heterogeneity < 0.001; and OR = 1.50, 95% CI: 1.36-1.65, p < 0.001), respectively. MetS is also more prevalent in individuals with the genetic variants rs3135506 and rs2075291. There was no evidence of a connection with rs126317.
CONCLUSIONS: The present findings suggest that polymorphisms located in the promoter and coding regions of the APOA5 gene are associated with an increased prevalence of MetS in the adult population. Identifying individuals with these genetic variations could lead to early disease detection and the implementation of preventive strategies to reduce the risk of MetS and its related health issues. However, because the sample size was small and there was evidence of significant heterogeneity for some APOA5 gene polymorphisms, these results need to be confirmed by more large-scale and well-designed studies.
METHODS: PubMed, Web of Science, Embase, and Scopus were searched up to April 2024. The random effects model was used to estimate the odds ratios (ORs) and 95% confidence intervals (CI) of the association between APOA5 gene polymorphisms and the prevalence of MetS development. The potential sources of heterogeneity were evaluated by subgroup analyses and sensitivity analyses.
RESULTS: A total of 30 studies with 54,986 subjects (25,341 MetS cases and 29,645 healthy controls) were included. The presence of rs662799 and rs651821 polymorphisms is associated with an approximately 1.5-fold higher likelihood of MetS prevalence (OR = 1.42, 95% CI: 1.32, 1.53, p < 0.001; I2 = 67.1%; P-heterogeneity < 0.001; and OR = 1.50, 95% CI: 1.36-1.65, p < 0.001), respectively. MetS is also more prevalent in individuals with the genetic variants rs3135506 and rs2075291. There was no evidence of a connection with rs126317.
CONCLUSIONS: The present findings suggest that polymorphisms located in the promoter and coding regions of the APOA5 gene are associated with an increased prevalence of MetS in the adult population. Identifying individuals with these genetic variations could lead to early disease detection and the implementation of preventive strategies to reduce the risk of MetS and its related health issues. However, because the sample size was small and there was evidence of significant heterogeneity for some APOA5 gene polymorphisms, these results need to be confirmed by more large-scale and well-designed studies.
摘要：
背景：载脂蛋白A5（APOA5）遗传多态性与代谢综合征（MetS）易感性之间的关联已被许多研究确定，但是文献中的结果相互矛盾。我们对观察性研究进行了荟萃分析，以评估APOA5基因多态性与MetS患病率之间的关联。
方法：PubMed，WebofScience,Embase,和Scopus被搜索到2024年4月。随机效应模型用于估计APOA5基因多态性与MetS发展患病率之间关联的比值比（ORs）和95％置信区间（CI）。通过亚组分析和敏感性分析评估异质性的潜在来源。
结果：共有30项研究纳入54,986名受试者（25,341例MetS病例和29,645名健康对照）。rs662799和rs651821多态性的存在与MetS患病率的可能性高约1.5倍相关（OR=1.42，95％CI：1.32，1.53，p<0.001；I2=67.1％；P异质性<0.001；OR=1.50，95％CI：1.36-1.65，p<0.001），分别。MetS在具有遗传变体rs3135506和rs2075291的个体中也更普遍。没有证据表明与rs126317有关。
结论：本研究结果表明，位于APOA5基因启动子区和编码区的多态性与成年人群中MetS的患病率增加有关。识别具有这些遗传变异的个体可以导致早期疾病检测和实施预防策略，以降低MetS及其相关健康问题的风险。然而,因为样本量很小，并且有证据表明某些APOA5基因多态性具有显着的异质性，这些结果需要更大规模和精心设计的研究来证实。
方法：PubMed，WebofScience,Embase,和Scopus被搜索到2024年4月。随机效应模型用于估计APOA5基因多态性与MetS发展患病率之间关联的比值比（ORs）和95％置信区间（CI）。通过亚组分析和敏感性分析评估异质性的潜在来源。
结果：共有30项研究纳入54,986名受试者（25,341例MetS病例和29,645名健康对照）。rs662799和rs651821多态性的存在与MetS患病率的可能性高约1.5倍相关（OR=1.42，95％CI：1.32，1.53，p<0.001；I2=67.1％；P异质性<0.001；OR=1.50，95％CI：1.36-1.65，p<0.001），分别。MetS在具有遗传变体rs3135506和rs2075291的个体中也更普遍。没有证据表明与rs126317有关。
结论：本研究结果表明，位于APOA5基因启动子区和编码区的多态性与成年人群中MetS的患病率增加有关。识别具有这些遗传变异的个体可以导致早期疾病检测和实施预防策略，以降低MetS及其相关健康问题的风险。然而,因为样本量很小，并且有证据表明某些APOA5基因多态性具有显着的异质性，这些结果需要更大规模和精心设计的研究来证实。
